Redeye: Transtema - Still set for a better 2025
Redeye retains its positive view of Transtema following a Q1 report with strong growth but a slightly lower y/y margin increase than expected.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/